Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376790 · ClinicalTrials.gov registry record · Phase 3
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 851
- Enrollment target
NCT02376790: Completed Phase 3 study, sponsored by Amgen.
NCT02376790 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 851 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02376790, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 851 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.
Primary Outcome
A positive ACR20 response is defined if the following 3 criteria for improvement from baseline were met: * ≥ 20% improvement in 68 tender joint count; * ≥ 20% improvement in 66 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of joint pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measu
Interventions
- DRUG Methotrexate
- DRUG Etanercept
- DRUG Placebo to Etanercept
- DRUG Placebo to Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 851 participants |
| Start Date | 2015-03-03 |
| Est. Completion | 2018-07-06 |
| Phase | Phase 3 |
What the finished NCT02376790 record still lists
NCT02376790 is an interventional study that assigns participants to a tested intervention. The registered 851 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 4 interventions - of which Methotrexate is the first listed.
NCT02376790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02376790 about?
NCT02376790 is a clinical study titled "Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis". The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.
What is the current status of trial NCT02376790?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 851 participants. The study started on 2015-03-03. Estimated completion is 2018-07-06.
What interventions are being tested in trial NCT02376790?
The interventions under investigation include: Methotrexate (DRUG), Etanercept (DRUG), Placebo to Etanercept (DRUG), Placebo to Methotrexate (DRUG).
Who is sponsoring clinical trial NCT02376790?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02376790's enrollment target sits among peer trials
851 386th of 2000 higher than 1,614 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06422143 · 851 participants · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI